Innovative Drugs At Center Of China’s 2024 Regulatory Efforts
Review Process, Pricing And Insurance On Agenda
The policies for China’s biopharma industry in 2024 centered around innovative small molecules, biologics and cell and gene therapies. Regulation changes for the industry in 2025 could be a continuation of that.